Clinical trials: Double-blind Randomized Controlled Study
Lung Cancer, Sarcopenia
Effects of Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients With Lung Cancer-related Sarcopenia
Sarcopenia is common in lung cancer patients. It is one of the significant factors affecting the overall survival, radiotherapy and chemotherapy efficacy, and quality of life of patients with lung cancer.
- Trial name
- NCT05771207
- Testing
- soy protein, whey protein
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Acute Kidney Injury
Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
The goal of this clinical trial is to repurpose cilastatin for preventing acute kidney injury (AKI) in hospitalized patients receiving nephrotoxic medications. The trial will evaluate the efficacy of the re-purposed drug.
- Trial name
- PONTiAK (NCT06886464)
- Testing
- Cilastatin Sodium
- Where
- 2 sites in Canada
- Volunteers
- 698 people
- Sponsor
- Matthew James
Healthy
Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
A Dual-center , Randomized, double-blinded and Parallel-controlled Study to Assess the Pharmacokinetic, pharmacodynamics, Safety and Immunogenicity of HS-20090 Injection and Xgeva® in Healthy Adults
- Trial name
- NCT05777109
- Testing
- HS-20090, Xgeva®
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Duchenne Muscular Dystrophy
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study.
- Trial name
- EMBARK (NCT05096221)
- Testing
- delandistrogene moxeparvovec
- Where
- 42 sites in United States, Belgium and 7 more
- Volunteers
- 126 people
- Sponsor
- Sarepta Therapeutics, Inc.
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not…
- Trial name
- NCT02289716
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Sleep Initiation and Maintenance Disorders
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
- Trial name
- NCT00426816
- Testing
- SB-649868
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Acute Blunt Soft Tissue Injuries/Contusions
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with acute blunt trauma injuries.
- Trial name
- NCT02290821
- Where
- 10 sites in United States
- Volunteers
- 215 people
- Sponsor
- Novartis
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Combination With DMARDs
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination with DMARDs versus DMARDs Alone in Patients with Rheumatoid…
- Trial name
- NCT01787149
- Testing
- DMARDs
- Where
- 7 sites in Taiwan
- Volunteers
- 98 people
- Sponsor
- Mycenax Biotech Inc.
Myocardial Fibrosis
Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction
Acute myocardial infarction (AMI) is myocardial necrosis caused by acute and continuous ischemia and hypoxia of coronary artery. It can be complicated with arrhythmia, shock or heart failure, which is often life-threatening.
- Trial name
- PROTECT-AMI (NCT05531955)
- Testing
- Pirfenidone Oral Capsule
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Schizophrenia
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.
- Trial name
- NCT01493726
- Testing
- ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alkermes, Inc.
Lung Cancer, Lung Metastases
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments' side effects will be studied together with quality of life.
- Trial name
- NCT02496585
- Testing
- Nintedanib, Prednisone
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with…
- Conditions
- Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis, Fibrosis, Lung Diseases, Interstitial
- Trial name
- NCT06383819
- Testing
- Longidaza®
- Where
- 30 sites in Russia
- Volunteers
- 392 people
- Sponsor
- NPO Petrovax
Elevated Blood Pressure, Hypertension
Study to Investigate the Potential Health Benefits of Grapes Seeds Extract Supplementation in the Management of Elevated Blood Pressure or Stage 1 Hypertension
This study is a pragmatic, randomized, double-blind, placebo-controlled trial aimed at evaluating the potential health benefits of Enovita® (standardized grape seed extract) supplementation in adults with elevated blood pressure…
- Trial name
- NCT06982365
- Testing
- Enovita® (Grape Seed Extract)
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Healthy Volunteer
A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects
This is a Phase I, single-center, three-arm, randomized, double-blind, active- and placebo-controlled study to investigate the effect of GDC-0449 on the QT/QTc interval in healthy female subjects of non-childbearing potential.
- Trial name
- NCT01173536
- Testing
- GDC-0449, moxifloxacin
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Herpes Genitalis
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in…
- Trial name
- NCT00079911
- Testing
- valacyclovir hydrochloride
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Dry Eye Syndromes
A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.
- Trial name
- NCT01427816
- Testing
- KCT-0809
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.
- Trial name
- BELIEVE-01 (NCT05234684)
- Testing
- Orelabrutinib + R-CHOP
- Where
- 44 sites in China
- Volunteers
- 150 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cystic Fibrosis
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03447249
- Testing
- VX-659/TEZ/IVA, IVA
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 385 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.